Related Experiment Video
Updated: May 23, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
The recombinant hepatitis B surface antigen vaccine in persons with HIV: is seroconversion sufficient for long-term
Jeff E Powis1, Janet Raboud, Mario Ostrowski
1Department of Medicine, University of Toronto, Ontario, Canada. jpowi@tegh.on.ca
Abstract:
A cohort of human immunodeficiency virus (HIV)-infected individuals with documented vaccine-induced hepatitis B surface antibody (HBsAb) seroconversion was evaluated retrospectively to determine factors associated with loss of protective levels of HBsAb. After a median follow-up of 43 months, 111 of the 152 participants (73%) maintained protective levels of HBsAb. HIV RNA suppression at vaccination was associated with persistence of protective levels of HBsAb (odds ratio, 3.83; P < .01). Booster doses were provided for those with loss of protective antibody levels, and hepatitis B virus-specific immune memory, as evaluated with T-cell proliferation assays, was poor despite the observation that boosters successfully reinduced protective levels of HBsAb.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature is...
Vaccinations
Hepatitis
Vaccines

